MA51915A - Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna) - Google Patents
Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna)Info
- Publication number
- MA51915A MA51915A MA051915A MA51915A MA51915A MA 51915 A MA51915 A MA 51915A MA 051915 A MA051915 A MA 051915A MA 51915 A MA51915 A MA 51915A MA 51915 A MA51915 A MA 51915A
- Authority
- MA
- Morocco
- Prior art keywords
- cedna
- transgenes
- closed
- regulated expression
- dna vectors
- Prior art date
Links
- 108700019146 Transgenes Proteins 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633757P | 2018-02-22 | 2018-02-22 | |
| US201862633795P | 2018-02-22 | 2018-02-22 | |
| US201862633882P | 2018-02-22 | 2018-02-22 | |
| US201862746762P | 2018-10-17 | 2018-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51915A true MA51915A (fr) | 2020-12-30 |
Family
ID=67687406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051915A MA51915A (fr) | 2018-02-22 | 2019-02-21 | Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220175970A1 (fr) |
| EP (1) | EP3755803A4 (fr) |
| JP (2) | JP2021513999A (fr) |
| KR (1) | KR20200124250A (fr) |
| CN (1) | CN111886343A (fr) |
| AU (1) | AU2019225937A1 (fr) |
| BR (1) | BR112020017060A2 (fr) |
| CA (1) | CA3092059A1 (fr) |
| IL (1) | IL276658A (fr) |
| MA (1) | MA51915A (fr) |
| MX (1) | MX2020008676A (fr) |
| PH (1) | PH12020551235A1 (fr) |
| SG (1) | SG11202007621TA (fr) |
| WO (1) | WO2019165050A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020002394A2 (pt) | 2017-08-09 | 2020-07-28 | Bioverativ Therapeutics Inc. | moléculas de ácidos nucleicos e usos das mesmas |
| KR102925832B1 (ko) | 2018-08-09 | 2026-02-11 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도 |
| AU2019376663A1 (en) * | 2018-11-09 | 2021-06-24 | Generation Bio Co. | Modified closed-ended DNA (ceDNA) comprising symmetrical modified inverted terminal repeats |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2021195218A1 (fr) * | 2020-03-24 | 2021-09-30 | Generation Bio Co. | Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques de la maladie de gaucher |
| AU2021244555A1 (en) * | 2020-03-24 | 2022-11-24 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
| EP4142758A4 (fr) * | 2020-04-28 | 2025-02-26 | President and Fellows of Harvard College | Système d'administration de gènes à haut rendement |
| AU2021297351A1 (en) * | 2020-06-26 | 2023-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting the human CCR5 locus as a safe harbor for the expression of therapeutic proteins |
| WO2022023284A1 (fr) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions de molécules d'adn, leurs procédés de fabrication et leurs procédés d'utilisation |
| US20220090130A1 (en) * | 2020-08-23 | 2022-03-24 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| EP4214309A4 (fr) * | 2020-09-16 | 2025-07-16 | Generation Bio Co | Vecteurs d'adn à extrémité fermée et utilisations associées pour exprimer de la phénylalanine hydroxylase (pah) |
| US20240181085A1 (en) * | 2021-03-19 | 2024-06-06 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing pfic therapeutics |
| WO2025114932A1 (fr) * | 2023-11-30 | 2025-06-05 | Sanofi | Purification de molécules d'adn à extrémité fermée |
| CN121662213B (zh) * | 2026-02-06 | 2026-04-21 | 湖南博极生命科技有限公司 | 基于注意力权重追溯的中药活性成分可解释性分析方法及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003087334A2 (fr) * | 2002-04-09 | 2003-10-23 | Cornell Research Foundation, Inc. | Utilisation d'element d'efficacite d'integration de virus adeno-associe (aav) permettant d'assurer la mediation d'une integration specifique de site d'une unite de transcription |
| DK2816118T3 (en) * | 2005-05-31 | 2018-12-03 | Univ Colorado Regents | Methods for delivery of genes |
| JP2010538675A (ja) * | 2007-09-19 | 2010-12-16 | アムステルダム モレキュラー セラピューティクス ビー.ブイ. | タンパク質産生の改善のためのaav複製機構の使用 |
| EP2500434A1 (fr) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique |
| US10577627B2 (en) * | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| WO2016037164A1 (fr) * | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Procédés et compositions pour atténuer des réponses immunitaires contre des vecteurs de transfert viraux modulant l'expression génique |
| EP3230451B1 (fr) * | 2014-12-12 | 2021-04-07 | The Broad Institute, Inc. | Arn guides protégés (pgrnas) |
| SG10201913688TA (en) * | 2016-03-03 | 2020-03-30 | Univ Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
-
2019
- 2019-02-21 JP JP2020544445A patent/JP2021513999A/ja active Pending
- 2019-02-21 US US16/971,016 patent/US20220175970A1/en active Pending
- 2019-02-21 BR BR112020017060-7A patent/BR112020017060A2/pt not_active Application Discontinuation
- 2019-02-21 WO PCT/US2019/018927 patent/WO2019165050A1/fr not_active Ceased
- 2019-02-21 MX MX2020008676A patent/MX2020008676A/es unknown
- 2019-02-21 CA CA3092059A patent/CA3092059A1/fr active Pending
- 2019-02-21 EP EP19757005.4A patent/EP3755803A4/fr active Pending
- 2019-02-21 AU AU2019225937A patent/AU2019225937A1/en not_active Abandoned
- 2019-02-21 KR KR1020207026566A patent/KR20200124250A/ko not_active Ceased
- 2019-02-21 CN CN201980019861.5A patent/CN111886343A/zh active Pending
- 2019-02-21 PH PH1/2020/551235A patent/PH12020551235A1/en unknown
- 2019-02-21 SG SG11202007621TA patent/SG11202007621TA/en unknown
- 2019-02-21 MA MA051915A patent/MA51915A/fr unknown
-
2020
- 2020-08-11 IL IL276658A patent/IL276658A/en unknown
-
2023
- 2023-12-08 JP JP2023207938A patent/JP2024028931A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020008676A (es) | 2020-09-25 |
| EP3755803A4 (fr) | 2022-01-19 |
| RU2020131041A (ru) | 2022-03-22 |
| CN111886343A (zh) | 2020-11-03 |
| EP3755803A1 (fr) | 2020-12-30 |
| US20220175970A1 (en) | 2022-06-09 |
| IL276658A (en) | 2020-09-30 |
| WO2019165050A1 (fr) | 2019-08-29 |
| CA3092059A1 (fr) | 2019-08-29 |
| JP2021513999A (ja) | 2021-06-03 |
| KR20200124250A (ko) | 2020-11-02 |
| JP2024028931A (ja) | 2024-03-05 |
| AU2019225937A1 (en) | 2020-08-13 |
| SG11202007621TA (en) | 2020-09-29 |
| PH12020551235A1 (en) | 2021-04-19 |
| BR112020017060A2 (pt) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51113A (fr) | Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce) | |
| EP3877548A4 (fr) | Séquençage massivement parallèle à l'aide de nucléotides non marqués | |
| MA51644A (fr) | Méthodes d'évaluation de la capacité de transduction de vecteurs viraux | |
| EP3899018A4 (fr) | Caractéristiques d'extrémité d'adn acellulaire | |
| MA52709A (fr) | Administration d'adn | |
| EP3504229A4 (fr) | Régulation de l'expression génique à l'aide de nucléases modifiées | |
| MA50942A (fr) | Protéines de liaison à l'adn modifiées | |
| EP3890786A4 (fr) | Vecteur viral adéno-associé recombiné pour l'insertion de gènes | |
| EP3833739A4 (fr) | Souche d'akkermansia muciniphila | |
| EP3968930A4 (fr) | Appareil d'aide à la mobilité | |
| EP3765023A4 (fr) | Vecteurs d'adn synthétiques et procédés d'utilisation | |
| EP3759131A4 (fr) | Identification de néo-antigène à l'aide de modèles pan-allèles | |
| EP3443014A4 (fr) | Constructions multi-spécifiques de liaison à l'antigène ciblant des agents immunothérapeutiques | |
| IL271389A (en) | Targeted non-viral dna insertions | |
| EP3411056A4 (fr) | Compositions pour lier des domaines de liaison à l'adn et des domaines de clivage | |
| EP3821011A4 (fr) | Séquençage d'adn/arn activé par transposome (séq-arn ted) | |
| MA51619A (fr) | Inhibiteurs de la protéine kinase dépendante de l'adn | |
| IL282885A (en) | Aav viral vectors and uses thereof | |
| EP3500675A4 (fr) | Méthodes d'édition de la méthylation de l'adn | |
| IL276658A (en) | Controlled expression of transgenes using closed-end DNA vectors | |
| MA54958A (fr) | Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée | |
| IL282456A (en) | Engineered dna polymerase variants | |
| EP3494210A4 (fr) | Pronostiqueur de mortalité basé sur la méthylation de l'adn | |
| EP3450569A4 (fr) | Procédé d'amplification d'adn | |
| EP3374903A4 (fr) | Séquençage rapide de fragments d'adn court à l'aide de la technologie des nanopores |